Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 13/11/2024

0,915 CHF (-3,89%)

(-3,89%) 13/11/2024

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d -3,89%
1 week1w -4,74%
1 maand1m -29,76%
3 maanden3m -58,01%
6 maanden6m -59,43%
1 jaar1j -57,15%
5 jaar5j -96,10%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

11 november 2024 · Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions · Persbericht

29 oktober 2024 · Idorsia announces financial results for the first nine months of 2024 · Persbericht

16 oktober 2024 · New data on aprocitentan to be presented at the ASN Kidney Week 2024 · Persbericht

17 september 2024 · Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 · Persbericht

5 september 2024 · New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 · Persbericht

2 september 2024 · Amended terms of Idorsia’s 2024 convertible bonds become effective · Persbericht

25 juli 2024 · Idorsia announces financial results for the first half 2024 · Persbericht

18 juli 2024 · Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call · Persbericht

1 juli 2024 · Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension · Persbericht

28 juni 2024 · Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds · Persbericht

Profiel Idorsia Ltd

CEO: Jean-Paul Clozel

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe